Cargando…

Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer

In locally advanced rectal cancer (LARC), an improved ability to predict prognosis before and after treatment is needed for individualized treatment. We aimed to utilize pre- and post-treatment clinical predictors and baseline magnetic resonance imaging (MRI) radiomic features for establishing progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Fei, Zhao, Qin, Li, Shuqi, Wu, Shuangshuang, Li, Jinli, Li, Haojiang, Chen, Shenghuan, Jiang, Wu, Dong, Annan, Wu, Liqing, Liu, Long, Huang, Huabin, Xu, Shuoyu, Shao, Yuanzhi, Liu, Lizhi, Li, Li, Cai, Peiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669703/
https://www.ncbi.nlm.nih.gov/pubmed/36408187
http://dx.doi.org/10.3389/fonc.2022.901287
_version_ 1784832178347048960
author Xie, Fei
Zhao, Qin
Li, Shuqi
Wu, Shuangshuang
Li, Jinli
Li, Haojiang
Chen, Shenghuan
Jiang, Wu
Dong, Annan
Wu, Liqing
Liu, Long
Huang, Huabin
Xu, Shuoyu
Shao, Yuanzhi
Liu, Lizhi
Li, Li
Cai, Peiqiang
author_facet Xie, Fei
Zhao, Qin
Li, Shuqi
Wu, Shuangshuang
Li, Jinli
Li, Haojiang
Chen, Shenghuan
Jiang, Wu
Dong, Annan
Wu, Liqing
Liu, Long
Huang, Huabin
Xu, Shuoyu
Shao, Yuanzhi
Liu, Lizhi
Li, Li
Cai, Peiqiang
author_sort Xie, Fei
collection PubMed
description In locally advanced rectal cancer (LARC), an improved ability to predict prognosis before and after treatment is needed for individualized treatment. We aimed to utilize pre- and post-treatment clinical predictors and baseline magnetic resonance imaging (MRI) radiomic features for establishing prognostic models to predict progression-free survival (PFS) in patients with LARC. Patients with LARC diagnosed between March 2014 and May 2016 were included in this retrospective study. A radiomic signature based on extracted MRI features and clinical prognostic models based on clinical features were constructed in the training cohort to predict 3-year PFS. C-indices were used to evaluate the predictive accuracies of the radiomic signature, clinical prognostic models, and integrated prognostic model (iPostM). In total, 166 consecutive patients were included (110 vs. 56 for training vs. validation). Eleven radiomic features were filtered out to construct the radiomic signature, which was significantly related to PFS. The MRI feature-derived radiomic signature exhibited better prognostic performance than the clinical prognostic models (P = 0.007 vs. 0.077). Then, we proposed an iPostM that combined the radiomic signature with tumor regression grade. The iPostM achieved the highest C-indices in the training and validation cohorts (0.942 and 0.752, respectively), outperforming other models in predicting PFS (all P < 0.05). Decision curve analysis and survival curves of the validation cohort verified that iPostM demonstrated the best performance and facilitated risk stratification. Therefore, iPostM provided the most reliable prognostic prediction for PFS in patients with LARC.
format Online
Article
Text
id pubmed-9669703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96697032022-11-18 Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer Xie, Fei Zhao, Qin Li, Shuqi Wu, Shuangshuang Li, Jinli Li, Haojiang Chen, Shenghuan Jiang, Wu Dong, Annan Wu, Liqing Liu, Long Huang, Huabin Xu, Shuoyu Shao, Yuanzhi Liu, Lizhi Li, Li Cai, Peiqiang Front Oncol Oncology In locally advanced rectal cancer (LARC), an improved ability to predict prognosis before and after treatment is needed for individualized treatment. We aimed to utilize pre- and post-treatment clinical predictors and baseline magnetic resonance imaging (MRI) radiomic features for establishing prognostic models to predict progression-free survival (PFS) in patients with LARC. Patients with LARC diagnosed between March 2014 and May 2016 were included in this retrospective study. A radiomic signature based on extracted MRI features and clinical prognostic models based on clinical features were constructed in the training cohort to predict 3-year PFS. C-indices were used to evaluate the predictive accuracies of the radiomic signature, clinical prognostic models, and integrated prognostic model (iPostM). In total, 166 consecutive patients were included (110 vs. 56 for training vs. validation). Eleven radiomic features were filtered out to construct the radiomic signature, which was significantly related to PFS. The MRI feature-derived radiomic signature exhibited better prognostic performance than the clinical prognostic models (P = 0.007 vs. 0.077). Then, we proposed an iPostM that combined the radiomic signature with tumor regression grade. The iPostM achieved the highest C-indices in the training and validation cohorts (0.942 and 0.752, respectively), outperforming other models in predicting PFS (all P < 0.05). Decision curve analysis and survival curves of the validation cohort verified that iPostM demonstrated the best performance and facilitated risk stratification. Therefore, iPostM provided the most reliable prognostic prediction for PFS in patients with LARC. Frontiers Media S.A. 2022-11-03 /pmc/articles/PMC9669703/ /pubmed/36408187 http://dx.doi.org/10.3389/fonc.2022.901287 Text en Copyright © 2022 Xie, Zhao, Li, Wu, Li, Li, Chen, Jiang, Dong, Wu, Liu, Huang, Xu, Shao, Liu, Li and Cai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Fei
Zhao, Qin
Li, Shuqi
Wu, Shuangshuang
Li, Jinli
Li, Haojiang
Chen, Shenghuan
Jiang, Wu
Dong, Annan
Wu, Liqing
Liu, Long
Huang, Huabin
Xu, Shuoyu
Shao, Yuanzhi
Liu, Lizhi
Li, Li
Cai, Peiqiang
Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer
title Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer
title_full Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer
title_fullStr Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer
title_full_unstemmed Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer
title_short Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer
title_sort establishment and validation of novel mri radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669703/
https://www.ncbi.nlm.nih.gov/pubmed/36408187
http://dx.doi.org/10.3389/fonc.2022.901287
work_keys_str_mv AT xiefei establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT zhaoqin establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT lishuqi establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT wushuangshuang establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT lijinli establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT lihaojiang establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT chenshenghuan establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT jiangwu establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT dongannan establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT wuliqing establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT liulong establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT huanghuabin establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT xushuoyu establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT shaoyuanzhi establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT liulizhi establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT lili establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer
AT caipeiqiang establishmentandvalidationofnovelmriradiomicfeaturebasedprognosticmodelstopredictprogressionfreesurvivalinlocallyadvancedrectalcancer